Category Archives: Media


EORTC, through SPECTAlung, participates in EU consortium validating blood-based cancer biomarkers

  Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer. Identification and analysis of these markers from blood is still exploratory, but they may offer an additional and extremely useful tool for modern

Read More


1 year in, SPECTAcolor is a viable cancer research model!

The EORTC is pleased to announce the successful implementation of SPECTAcolor, ‘Screening Patients for Efficient Clinical Trial Access’ – the first Pan European collaborative molecular screening platform for colorectal cancer patients. SPECTAcolor proves the logistical feasibility of the infrastructure that was built to run next generation trials in a multinational setting. Now one year into

Read More


SPECTAforum 2014: Videos available for viewing

The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms

Read More


EORTC hosts first SPECTAforum, Screening Program for Efficient Clinical Trial Access, in Brussels

The first European multi-stakeholder model to address biomarker based drug development and promote innovative partnership successfully gathered in Brussels on 07 November 2013. The meeting convened circa 80 selected representatives of patient groups, academic researchers, regulators, government, European Union commission, pharmaceutical industry sector, and diagnostic and technology companies alongside EORTC officers and representatives. Without a

Read More